Opdivo is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) after Autologous Stem Cell Transplant (ASCT) and treatment with brentuximab vedotin.

INN:

Subtype:

Hodgkin Lymphoma (HL)

License:

EMA

Class:

PD-1 inhibitor

R/R

SmPC: https://www.medicines.org.uk/emc/medicine/30476 

1. Approved Labelling 

Opdivo is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) after Autologous Stem Cell Transplant (ASCT) and treatment with brentuximab vedotin.

 2. Treatment Regimen 

The recommended dose of Opdivo is 3 mg/kg nivolumab administered intravenously over 60 minutes every 2 weeks. 

Opdivo is for intravenous use only. It is to be administered as an intravenous infusion over a period of 60 minutes. The infusion must be administered through a sterile, non-pyrogenic, low protein binding in-line filter with a pore size of 0.2-1.2 μm.

Opdivo must not be administered as an intravenous push or bolus injection.

The total dose of Opdivo required can be infused directly as a 10 mg/mL solution or can be diluted to as low as 1 mg/mL with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection.

3. AE/ Warnings

Please see section 4.4 of the SmPC.

 

 

Disclaimer: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.